137719-32-5

Basic information

• Product Name: 2-amino-9-[(2R,5S)-5-(hydroxymethyl)tetrahydrothiophen-2-yl]-3,9-dihydro-6H-purin-6-one
• CAS NO: 137719-32-5
• Molecular Formula: C₁₀H₁₃N₅O₂S
• Molecular Weight: 267.3075
• Mol File: 137719-32-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 655°C at 760 mmHg
• Flash Point: 349.9°C
• Density: 1.92g/cm³
• Vapor Pressure: 4.76E-18mmHg at 25°C
• Refractive Index: 1.918
• CAS DataBase Reference: 2-amino-9-[(2R,5S)-5-(hydroxymethyl)tetrahydrothiophen-2-yl]-3,9-dihydro-6H-purin-6-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-9-[(2R,5S)-5-(hydroxymethyl)tetrahydrothiophen-2-yl]-3,9-dihydro-6H-purin-6-one(137719-32-5)
• EPA Substance Registry System: 2-amino-9-[(2R,5S)-5-(hydroxymethyl)tetrahydrothiophen-2-yl]-3,9-dihydro-6H-purin-6-one(137719-32-5)

Safety Data

• Hazardous Substances Data: 137719-32-5(Hazardous Substances Data)

Usage

Type

Synthetic nucleoside analog reverse transcriptase inhibitor (NRTI)

Use

Treatment of HIV/AIDS

Mechanism of action

Inhibits the replication of the HIV virus by stopping the reverse transcriptase enzyme from functioning properly

Administration

Orally; available in various formulations such as tablets, oral solution, and injectable formulations

Combination therapy

Often used in combination with other antiretroviral medications

Side effects

Potential side effects; should be used with caution in patients with certain medical conditions

Upstream product

• 137719-31-4 2-amino-2',3'-dideoxy-4'-thioadenosine 
• 137819-72-8 9-<5-O-(tert-butyldiphenylsilyl)-2,3-dideoxy-4-thio-β-ribofuranosyl>-2,6-dichloropurine 
• 137719-30-3 2-amino-5'-O-(tert-butyldiphenylsilyl)-2',3'-dideoxy-4'-thioadenosine 
• 137719-21-2 4(S)-(acetylthio)-5-<(tert-butyldiphenylsilyl)oxy>pentanoic acid methyl ester 
• 137719-23-4 1-O-acetyl-5-O-(tert-butyldiphenylsilyl)-2,3-dideoxy-4-thioribofuranose 

Relevant articles and documents

2',3'-dideoxy-4'-thioribonucleosides and synthetic precursors thereof

2',3'-dideoxy-4'-thioribonucleosides useful as antiviral agents in the treatment and prevention of AIDS are disclosed. In accordance with one aspect of the invention there are provided compounds of the formula STR1 where X=H, N3 or F, and B is a member selected from the group consisting of pyrimidine, 5-azapyrimidine, 6-azapyrimidine, 3-deazapyrimidine, purine, 3-deazapurine, 7-deazapurine, 8-azapurine, and 2-azapurine bases. The intermediate 1-O-acetyl-5-O-t-butyldiphenylsilyl-4-thio-2,3-dideoxyribofuranose is useful in the production of certain of the 2',3'-dideoxy-4'-thioribonucleosides. Other intermediates include the 4-thio-2,3-dideoxyribofuranose having different hydroxyl protecting groups and leaving groups.

2',3'-dideoxy-4'-thioribonucleosides as antiviral agents

2'3'-dideoxy-4'-thioribonucleosides useful as antiviral agents in the treatment and prevention of AIDS are disclosed. In accordance with one aspect of the invention there are provided compounds of the formula STR1 where X=H, N3 or F, and B is a member selected from the group consisting of pyrimidine, 5-azapyrimidine, 6-azapyrimidine, 3-deazapyrimidine, purine, 3-deazapurine, 7-deazapurine, 8-azapurine, and 2-azapurine bases. The intermediate 1-O-acetyl-5-O-t-butyldiphenylsilyl-4-thio-2,3-dideoxyribofuranose useful in the production of certain of the 2',3'-dideoxy-4'-thioribonucleosides is also disclosed.